MIRM - Mirum Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$142.55
DETAILS
HIGH:
$185.00
LOW:
$118.00
MEDIAN:
$140.00
CONSENSUS:
$142.55
UPSIDE:
44.54%
About Mirum Pharmaceuticals, Inc. (https://www.mirumpharma.com)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Christopher Peetz | Chief Executive Officer & Director | 1979 | $1,826,000 USD |
| Peter Radovich | Chief Operating Officer & President | 1978 | $1,159,000 USD |
| Eric H. Bjerkholt | Chief Financial Officer | 1960 | $1,002,000 USD |
| Joanne J. Quan | Chief Medical Officer | 1964 | $1,002,000 USD |
| Lara Longpre | Chief Development Officer | 1970 | $678,200 USD |
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations | – | – |
| Douglas T. Sheehy | Chief Legal Officer & Secretary | 1967 | – |
| Erin Campany | Chief People Officer | 1968 | – |
| Jean-Luc Girardet | Chief Technical Officer | – | – |
| Meredith Kiernan | Senior Director of Global Corporate Communications | – | – |
| Vinita Kumar | Senior Vice President of Quality | – | – |